Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/MDMA/Personality Disorders

MDMA for Personality Disorders

1 paper and 3 clinical trials exploring mdma as a treatment for personality disorders.

Compoundempathogen

MDMA

MDMA is a synthetic empathogen that enhances monoamine release, producing prosocial and anxiolytic effects without frank hallucinosis. Two Phase III trials demonstrated significant PTSD symptom reductions, though FDA review raised concerns about blinding, durability, and safety characterisation.

Full MDMA profile
IndicationApproximately 9% of adults globally.

Personality Disorders

Personality disorders, characterised by enduring patterns of behaviour, cognition, and inner experience, present substantial challenges in treatment. Emerging research into psychedelics such as psilocybin, MDMA, and ketamine indicates that they may offer novel therapeutic avenues for addressing these complex conditions.

Full Personality Disorders profile

Academic Research

1 paper
Paywallmeta

MDMA-Assisted Psychotherapy for Borderline Personality Disorder

This review (2022) makes the cases for using MDMA-assisted therapy (MDMA-AT) in the treatment of borderline personality disorder (BPD). The authors draw parallels between using MDMA-AT to treat disorders similar to BPD, such as PTSD, and provide considerations for designing future clinical trials.

Published
October 25, 2022
Journal
Focus
Authors
Traynor, J. M., Roberts, D. E., Ross, S., Zeifman, R., Choi-Kain, L.

Clinical Trials

3 trials
RecruitingPhase II

MDMA in Borderline Personality Disorder (MDMA in BPD)

This open-label trial (n=10) will investigate the effects of a single dose of MDMA on social cognition in adults with Borderline Personality Disorder (BPD).

Started
February 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06683014
Active not recruitingPhase I

MDMA-Assisted Therapy for Pathological Narcissism

This open-label, proof-of-concept pilot study (n=12) will assess the efficacy and safety of midomafetamine (MDMA)-assisted therapy (MDMA-AT) with three monthly experimental dosing sessions (80 mg first; 120 mg second and third; optional 50% supplemental dose).

Started
August 27, 2024
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06565494
Not yet recruitingPhase II

Pilot investigation of psychedelic-assisted psychotherapy for treatment of post-traumatic stress disorder (PTSD) in people diagnosed with co-occurring borderline personality disorder – a controlled before-and-after study

This interventional controlled study (n=20) will evaluate GPM-Complex psychotherapy with or without 2–5 MDMA-assisted sessions (initial 80 mg with optional 40 mg supplemental dose) for treating PTSD in individuals with co-occurring BPD.

Started
July 26, 2024
Type
interventional
Blinding
none
Randomized
No
Registry ID
ACTRN12624000871549

Explore further

Search all MDMA papers Search all Personality Disorders trials Full MDMA profile Full Personality Disorders profile